The previously published
murine BRafV600E cell lines are relatively resistant to PLX4032 and PLX4720 treatment compared to
human BRAFV600E cell lines, with respect to decreased pERK signaling and cellular proliferation (Hooijkaas
et al., 2012b; Knight et al., 2013; Koya et al., 2012).